Unknown

Dataset Information

0

Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma.

ABSTRACT: BACKGROUND:Circulating tumor DNA (ctDNA) is a biomarker for the selection of target agents in various malignancies. In this study, we examined the effect of ctDNA presence on the response to EGFR-tyrosine kinase inhibitor (TKI) and on the prognosis in lung adenocarcinoma. METHODS:ctDNA of EGFR-TKI sensitizing mutations (mEGFR), L858R substitution and Exon 19 deletion (E19d) mutation, was evaluated using droplet digital PCR (ddPCR) in 81 patients with lung adenocarcinoma which harbored mEGFR in the corresponding tumor tissues. RESULTS:The study recruited lung cancer patients at various stages, and the sensitivity, specificity, and area under the curve (AUC) of mEGFR ctDNA detection by ddPCR were 40.0%, 88.5%, and 0.68, respectively. It showed higher sensitivity (75.0% vs. 10.0%) and AUC (0.83 vs. 0.49) in the advanced stages of lung adenocarcinoma compared with the early stages and the number of metastases and the fractional abundance of mEGFR ctDNA showed a strong correlation (? = 0.516; P?

SUBMITTER: Kim T 

PROVIDER: S-EPMC6885440 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma.

Kim Taehee T   Kim Eun Young EY   Lee Sang Hoon SH   Kwon Do Sun DS   Kim Arum A   Chang Yoon Soo YS  

Thoracic cancer 20191024 12

<h4>Background</h4>Circulating tumor DNA (ctDNA) is a biomarker for the selection of target agents in various malignancies. In this study, we examined the effect of ctDNA presence on the response to EGFR-tyrosine kinase inhibitor (TKI) and on the prognosis in lung adenocarcinoma.<h4>Methods</h4>ctDNA of EGFR-TKI sensitizing mutations (mEGFR), L858R substitution and Exon 19 deletion (E19d) mutation, was evaluated using droplet digital PCR (ddPCR) in 81 patients with lung adenocarcinoma which harb  ...[more]

Similar Datasets

Unknown Stromal LRP1 in lung adenocarcinoma predicts clinical outcome.
| S-EPMC3079007 | biostudies-literature
Unknown BRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasion.
| S-EPMC4994180 | biostudies-literature
Unknown CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients.
| S-EPMC5386720 | biostudies-literature
Unknown TOP2A Promotes Lung Adenocarcinoma Cells' Malignant Progression and Predicts Poor Prognosis in Lung Adenocarcinoma.
| S-EPMC7066024 | biostudies-literature
Unknown Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma.
| S-EPMC8127640 | biostudies-literature
Transcriptomics COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
2014-01-01 | GSE44104 | GEO
Transcriptomics COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
2014-01-01 | E-GEOD-44104 | biostudies-arrayexpress
Transcriptomics Early-Stage Lung adenocarcinoma MDM2 genomic heterogeneity predicts clinical outcome and response to targeted therapy
2022-12-31 | GSE191171 | GEO
Unknown Presence of Systemic Inflammatory Response Syndrome Predicts a Poor Clinical Outcome in Dogs with a Primary Hepatitis.
| S-EPMC4726575 | biostudies-literature
Unknown Eosinophil peroxidase over-expression predicts the clinical outcome of patients with primary lung adenocarcinoma.
| S-EPMC6400814 | biostudies-literature